Protara Therapeutics TARA Q1 2026 Earnings Narrower Loss Beats Street Estimates on Cost Management PHI Q1 2026 Earnings EPS Misses Estimates but Stock Inches Higher BGS Q1 2026 Earnings Earnings Beat Driven by Cost Discipline and Portfolio Optimization AFB Q3 2024 Earnings Steady Earnings Amid Stable Municipal Market Conditions vTv Therapeutics Inc Q1 2026 Earnings Massive EPS Surprise Amid Revenue Shortfall and Stock Decline Sweetgreen Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Movement